Clinical trial
A Study of Lasmiditan (LY573144) Over Four Migraine Attacks
The reason for this study is to see how effective and safe the study drug known as lasmiditan is in the acute treatment of 4 migraine attacks with or without aura.
Study Type: Interventional (Clinical Trial)
Estimated Enrollment: 1600 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Randomized Controlled Trial of Lasmiditan Over Four Migraine Attacks
Actual Study Start Date: June 24, 2019
Estimated Primary Completion Date: March 26, 2020
Estimated Study Completion Date: March 29, 2021
Arms:
- Experimental: Lasmiditan High Dose
- Experimental: Lasmiditan Low Dose
- Placebo Comparator: Control
| Category | Value |
|---|---|
| Date last updated at source | 2019-11-19 |
| Study type(s) | Interventional |
| Expected enrolment | 1600 |
| Study start date | 2019-06-24 |
| Estimated primary completion date | 2020-03-26 |